Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management
(2010) In Leukemia 24(6). p.1121-1127- Abstract
- Monoclonal gammopathy of undetermined significance (MGUS) was identified in 3.2% of 21 463 residents of Olmsted County, Minnesota, 50 years of age or older. The risk of progression to multiple myeloma, Waldenstrom's macroglobulinemia, AL amyloidosis or a lymphoproliferative disorder is approximately 1% per year. Low-risk MGUS is characterized by having an M protein < 15 g/l, IgG type and a normal free light chain (FLC) ratio. Patients should be followed with serum protein electrophoresis at six months and, if stable, can be followed every 2-3 years or when symptoms suggestive of a plasma cell malignancy arise. Patients with intermediate and high-risk MGUS should be followed in 6 months and then annually for life. The risk of smoldering... (More)
- Monoclonal gammopathy of undetermined significance (MGUS) was identified in 3.2% of 21 463 residents of Olmsted County, Minnesota, 50 years of age or older. The risk of progression to multiple myeloma, Waldenstrom's macroglobulinemia, AL amyloidosis or a lymphoproliferative disorder is approximately 1% per year. Low-risk MGUS is characterized by having an M protein < 15 g/l, IgG type and a normal free light chain (FLC) ratio. Patients should be followed with serum protein electrophoresis at six months and, if stable, can be followed every 2-3 years or when symptoms suggestive of a plasma cell malignancy arise. Patients with intermediate and high-risk MGUS should be followed in 6 months and then annually for life. The risk of smoldering (asymptomatic) multiple myeloma (SMM) progressing to multiple myeloma or a related disorder is 10% per year for the first 5 years, 3% per year for the next 5 years and 1-2% per year for the next 10 years. Testing should be done 2-3 months after the initial recognition of SMM. If the results are stable, the patient should be followed every 4-6 months for 1 year and, if stable, every 6-12 months. Leukemia (2010) 24, 1121-1127; doi:10.1038/leu.2010.60; published online 22 April 2010 (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1630894
- author
- organization
- publishing date
- 2010
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- MGUS, International Myeloma Working Group, myeloma, monoclonal gammopathy of undetermined significance, smoldering multiple
- in
- Leukemia
- volume
- 24
- issue
- 6
- pages
- 1121 - 1127
- publisher
- Nature Publishing Group
- external identifiers
-
- wos:000278575400003
- scopus:77954610729
- pmid:20410922
- ISSN
- 1476-5551
- DOI
- 10.1038/leu.2010.60
- language
- English
- LU publication?
- yes
- id
- 72c6e179-5f02-4989-a57e-83864ed52b3c (old id 1630894)
- date added to LUP
- 2016-04-01 14:24:10
- date last changed
- 2022-05-15 18:28:15
@article{72c6e179-5f02-4989-a57e-83864ed52b3c, abstract = {{Monoclonal gammopathy of undetermined significance (MGUS) was identified in 3.2% of 21 463 residents of Olmsted County, Minnesota, 50 years of age or older. The risk of progression to multiple myeloma, Waldenstrom's macroglobulinemia, AL amyloidosis or a lymphoproliferative disorder is approximately 1% per year. Low-risk MGUS is characterized by having an M protein < 15 g/l, IgG type and a normal free light chain (FLC) ratio. Patients should be followed with serum protein electrophoresis at six months and, if stable, can be followed every 2-3 years or when symptoms suggestive of a plasma cell malignancy arise. Patients with intermediate and high-risk MGUS should be followed in 6 months and then annually for life. The risk of smoldering (asymptomatic) multiple myeloma (SMM) progressing to multiple myeloma or a related disorder is 10% per year for the first 5 years, 3% per year for the next 5 years and 1-2% per year for the next 10 years. Testing should be done 2-3 months after the initial recognition of SMM. If the results are stable, the patient should be followed every 4-6 months for 1 year and, if stable, every 6-12 months. Leukemia (2010) 24, 1121-1127; doi:10.1038/leu.2010.60; published online 22 April 2010}}, author = {{Kyle, R. A. and Durie, B. G. M. and Rajkumar, S. V. and Landgren, O. and Blade, J. and Merlini, G. and Kroeger, N. and Einsele, H. and Vesole, D. H. and Dimopoulos, M. and San Miguel, J. and Avet-Loiseau, H. and Hajek, R. and Chen, W. M. and Anderson, K. C. and Ludwig, H. and Sonneveld, P. and Pavlovsky, S. and Palumbo, A. and Richardson, P. G. and Barlogie, B. and Greipp, P. and Vescio, R. and Turesson, Ingemar and Westin, J. and Boccadoro, M.}}, issn = {{1476-5551}}, keywords = {{MGUS; International Myeloma Working Group; myeloma; monoclonal gammopathy of undetermined significance; smoldering multiple}}, language = {{eng}}, number = {{6}}, pages = {{1121--1127}}, publisher = {{Nature Publishing Group}}, series = {{Leukemia}}, title = {{Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management}}, url = {{http://dx.doi.org/10.1038/leu.2010.60}}, doi = {{10.1038/leu.2010.60}}, volume = {{24}}, year = {{2010}}, }